Latest News - JAK inhibitors

Thursday, September 14, 2017

Lilly’s Baricitinib Performs Well in Phase 2 AD Study

Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatiti…

Read the full story